News & Analysis
The CAR-T Revolution: Gilead’s Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies
The CAR-T Revolution: Gilead’s Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies
More
Share
Evolution Infographics
Autologous CAR-T Cell Therapies: is this the Beginning or the End?
Autologous CAR-T Cell Therapies: is this the Beginning or the End?
More
Share
Evolution Infographics
Cancer Immunotherapy: A Historical Timeline & Exploration of the Prior Art Paradox
Cancer Immunotherapy: A Historical Timeline & Exploration of the Prior Art Paradox
More
Share
News & Analysis
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic

More
Share